Michael Thomas

20PUBLICATIONS
79CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersChemotherapyEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Apr 20, 2026
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Mar 24, 2026
Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315).

Fabian Acker, Katharina Wenger, Martin Reck

|Sep 25, 2024
Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome.

Marcel Wiesweg, Claudia Küter, Johannes Schnorbach

|Sep 14, 2024
Peripheral Inflammation Featuring Eosinophilia or Neutrophilia Is Associated with the Survival and Infiltration of Eosinophils within the Tumor among Various Histological Subgroups of Patients with NSCLC.

Bilal Alashkar Alhamwe, Kadriya Yuskaeva, Friederike Wulf

|Feb 08, 2024
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315).

Martin Sebastian, Wilfried E E Eberhardt, Eyck von der Heyde

Pageof 4

Frequent Collaborators

6 joint publications

Albrecht Stenzinger

4 joint publications

Volker Endris

4 joint publications

Jan Budczies

3 joint publications

Thomas Muley